Reimagining oncology: AI, multiomics, spatial data and the shift to personalised cancer care
Wahid Awad, Founder and CEO of Rosetta Omics, joined Muhammad Younis for an insightful discussion on the future of precision oncology.
Q1. What is the biggest challenge in making personalised treatment the standard of care?
One of the biggest challenges is the lack of comprehensive, clinically validated predictive tools that can guide treatment selection in real time. Many current approaches still rely on broad treatment guidelines rather than precise molecular insights tailored to individual patients. Bridging this gap requires a holistic approach that combines spatial multiomics, real-world clinical data, and AI-driven decision support.
Q2. How can AI, multiomics, and spatial data change oncology?
By integrating spatial multiomics with AI, we can map the tumor microenvironment with unprecedented precision, identify novel biomarkers, and predict treatment responses with greater accuracy, moving oncology from a one-size-fits-all approach to truly personalised medicine.
Q3. What is Rosetta Omics doing differently?
We combine spatial multiomics, AI-driven analytics, and real-world clinical insights. Unlike platforms that focus on a single omics layer, we integrate multiple molecular layers within their spatial context for a far more comprehensive view of tumor biology.
Q4. How can personalised medicine become more accessible?
Advances in AI, automation, and high-throughput omics are rapidly making it more affordable. The key lies in scalability, standardisation, and integration into existing clinical workflows, plus strong partnerships between biotech, pharma, healthcare providers and policymakers.
Q5. What role does collaboration play?
Collaboration is the cornerstone of progress. Biotech innovators bring AI and multiomics solutions, pharma drives drug development and clinical validation, and healthcare providers integrate these advances into patient care.
Q6. What's next for Rosetta Omics?
Expanding our AI-driven multiomics platform, refining our predictive models, and forging strategic partnerships with leading hospitals, pharma companies, and research institutions to bring precision oncology to clinical practice on a global scale.